

Marta Jimenez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9790876/publications.pdf>

Version: 2024-02-01

10
papers

1,118
citations

1163117

8
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

2406
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic characterization of metastatic breast cancers. <i>Nature</i> , 2019, 569, 560-564.	27.8	448
2	Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIRO1/UNICANCER). <i>Lancet Oncology</i> , The, 2014, 15, 267-274.	10.7	351
3	CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies from the French OS2006 phase 3 trial. <i>OncoImmunology</i> , 2017, 6, e1331193.	4.6	141
4	Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIRO2-BREAST IMMUNO trial. <i>Nature Medicine</i> , 2021, 27, 250-255.	30.7	85
5	Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 941-948.	2.4	24
6	Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation. <i>European Journal of Cancer</i> , 2021, 159, 283-295.	2.8	24
7	Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients. <i>Oncotarget</i> , 2017, 8, 83570-83584.	1.8	18
8	Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis. <i>Cancer Research</i> , 2022, 82, 974-985.	0.9	14
9	A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). <i>European Journal of Cancer</i> , 2021, 158, 169-180.	2.8	9
10	Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIRO2-Lung/IFCT 1301 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 4018-4026.	7.0	4